Alantra advises OrganiCare on the sale of FemiClear and Curoxen to Venture Life Group

Jun 2026

Sell-side advisory

New York – Alantra acted as exclusive financial advisor to OrganiCare, a U.S.-based consumer healthcare company, on the sale of its FemiClear® and Curoxen® brands to Venture Life Group plc (“VLG”), an international consumer self-care company.

FemiClear and Curoxen are differentiated natural and homeopathic OTC consumer healthcare brands addressing the women’s health and wound care categories. The acquisition expands VLG’s presence in women’s health through the addition of FemiClear and establishes a strategic foothold in the U.S. market, further strengthening the company’s international consumer healthcare platform.

Venture Life Group develops, manufactures and commercializes products across a range of health and wellness categories, including women’s health, oral care, glucose management, oncology support and other self-care segments. The company has a commercial presence in more than 90 countries worldwide.

Alantra drew on its consumer healthcare and OTC sector expertise to navigate the complexities associated with marketing and valuing homeopathic healthcare brands in the U.S. market. The team supported buyer diligence around the regulatory framework, commercial dynamics and growth opportunities underpinning the FemiClear and Curoxen brands, while managing a targeted cross-border process that resulted in a successful transaction for OrganiCare.

Rusty Ray, Managing Partner at Alantra, said: “We are pleased to have advised OrganiCare on this transaction, which brings FemiClear and Curoxen into a broader international consumer healthcare platform. The deal reflects continued strategic interest in differentiated self-care brands and highlights Alantra’s ability to support cross-border consumer health transactions involving category-specific regulatory and commercial considerations.”

This transaction reinforces Alantra’s activity in Consumer Health, with recent transactions including advising 21st Century Healthcare on its sale to Grant Avenue Capital, Venture Life Group plc on the sale of its CDMO business and selected non-core products to BioDue, and Perrigo on the divestment of Richard Bittner to DCC Healthcare.